E Fund Management Co. Ltd. Acquires 2,112 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

E Fund Management Co. Ltd. lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 75.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,926 shares of the biopharmaceutical company's stock after acquiring an additional 2,112 shares during the quarter. E Fund Management Co. Ltd.'s holdings in Alnylam Pharmaceuticals were worth $1,197,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company's stock worth $2,286,181,000 after acquiring an additional 287,064 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 12,513 shares in the last quarter. Quattro Financial Advisors LLC lifted its position in Alnylam Pharmaceuticals by 2,517.8% during the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company's stock valued at $747,000 after buying an additional 4,809 shares during the period. Plato Investment Management Ltd boosted its holdings in shares of Alnylam Pharmaceuticals by 2,666.3% during the 1st quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company's stock valued at $674,000 after buying an additional 4,346 shares in the last quarter. Finally, SteelPeak Wealth LLC grew its position in shares of Alnylam Pharmaceuticals by 147.7% in the 1st quarter. SteelPeak Wealth LLC now owns 6,860 shares of the biopharmaceutical company's stock worth $1,025,000 after buying an additional 4,090 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ALNY shares. BMO Capital Markets reiterated an "outperform" rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, June 24th. JPMorgan Chase & Co. upped their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a "neutral" rating in a research note on Monday, August 26th. Royal Bank of Canada restated an "outperform" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 4th. Barclays increased their target price on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the company an "overweight" rating in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, September 9th. Seven investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $279.14.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded down $1.31 during trading hours on Wednesday, reaching $273.15. 630,722 shares of the company traded hands, compared to its average volume of 890,453. The firm has a 50-day moving average price of $259.23 and a 200 day moving average price of $196.79. The company has a market cap of $34.55 billion, a P/E ratio of -102.41 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analysts' expectations of $447.22 million. Alnylam Pharmaceuticals's revenue for the quarter was up 107.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.21) EPS. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Insider Buying and Selling

In related news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the sale, the director now owns 136 shares in the company, valued at $30,013.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the transaction, the chief executive officer now owns 80,534 shares of the company's stock, valued at approximately $18,602,548.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David E. I. Pyott sold 32,450 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at $30,013.84. The disclosure for this sale can be found here. In the last quarter, insiders sold 103,148 shares of company stock valued at $25,658,824. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.